Semaglutide’s U.S. patents keep generics out until around 2031 or 2035, maintaining Novo Nordisk’s exclusivity and high ...

Cystic fibrosis causes a buildup of mucus in the lungs that can lead to infection, and often death in children and young ...

Allos AI today announced $5 million in seed financing led by Oxford Science Enterprises (OSE) to commercialize the industry's ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

The global market for generic drugs estimated at $430.2 billion in 2023, is projected to reach a revised size of $671.5 billion by 2030, growing at a CAGR of 5.7% over the analysis period 2023-2030, ...

The cost of medication was too high for thousands of CF sufferers around the world. Now a Bangladeshi company is making a generic version that will change lives ...

Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics ...

Indian drugmakers primarily produce generics, or copycat versions, and in order to enter the market, they either have to wait ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing drugs on ...

ADHD is a neurodevelopmental condition that affects both children and adults. It is characterised by symptoms such as ...